<SEC-DOCUMENT>0001193125-25-337097.txt : 20251230
<SEC-HEADER>0001193125-25-337097.hdr.sgml : 20251230
<ACCEPTANCE-DATETIME>20251230161101
ACCESSION NUMBER:		0001193125-25-337097
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220921
FILED AS OF DATE:		20251230
DATE AS OF CHANGE:		20251230

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Badawi David
		CENTRAL INDEX KEY:			0001870825
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40587
		FILM NUMBER:		251614381

	MAIL ADDRESS:	
		STREET 1:		C/O SIGHT SCIENCES, INC.
		STREET 2:		4040 CAMPBELL AVENUE, SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sight Sciences, Inc.
		CENTRAL INDEX KEY:			0001531177
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				800625749
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		4040 CAMPBELL AVE,
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		(415) 889-0550

	MAIL ADDRESS:	
		STREET 1:		4040 CAMPBELL AVE,
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4/A
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2022-09-21</periodOfReport>

    <dateOfOriginalSubmission>2022-09-21</dateOfOriginalSubmission>

    <issuer>
        <issuerCik>0001531177</issuerCik>
        <issuerName>Sight Sciences, Inc.</issuerName>
        <issuerTradingSymbol>SGHT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001870825</rptOwnerCik>
            <rptOwnerName>Badawi David</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SIGHT SCIENCES, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>4040 CAMPBELL AVE., SUITE 100</rptOwnerStreet2>
            <rptOwnerCity>MENLO PARK</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94025</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>Chief Technology Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1448656</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.23</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2022-09-21</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>40000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2026-02-28</value>
                <footnoteId id="F3"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>40000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>42540</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F4"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Includes 1,441,196 shares that were previously reported as beneficially owned on the Reporting Person's Form 3 filed on July 14, 2021, as well as 7,460 shares that were acquired by the Reporting Person upon exercise of options prior to the Issuer's completion of the Initial Public Offering in July 2021 that should have been included under Column 2 of Table I of the Form 3 but were inadvertently included as shares underlying options with an exercise price of $0.23 that expire on February 28, 2026 under Column 3 of Table II of the Form 3.</footnote>
        <footnote id="F2">The grant of stock options (&quot;Options&quot;) made to the Reporting Person vested and became exercisable as to 25% of the underlying shares on January 1, 2017, and as to the remainder of such shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date, such that all such Options shall be fully vested and exercisable on January 1, 2020.</footnote>
        <footnote id="F3">The original Form 4 filing identified the expiration date of the relevant Options as 01/08/2027. This amendment corrects the expiration date of the relevant Options to February 28, 2026.</footnote>
        <footnote id="F4">Excludes the 7,460 shares that were previously inadvertently included as described in footnote (1) to this Form 4.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/Jeremy Hayden, Attorney-in-Fact for David Badawi</signatureName>
        <signatureDate>2025-12-30</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
